Basic Information
| LncRNA/CircRNA Name | DUXAP10 |
| Synonyms | PCAN-3 |
| Region | GRCh38_14:19294785-19337674 |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | esophageal squamous cell carcinoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, RIP, other |
| Sample | ESCC tissues and cells (KYSE30, KYSE510, KYSE180, KYSE150 and NE1) |
| Expression Pattern | up-regulated |
| Function Description | In this study, DUXAP10 was certified to be upregulated in ESCC tissues and cells. Besides, it was positively correlated with short survival time. Moreover, down-expression of DUXAP10 contributed to decreased cell proliferation and metastasis. Silenced DUXAP10 led to increased apoptosis rate and stagnation of cell cycle. Results of mechanism experiments suggested that DUXAP10 motivated ESCC progression through recruiting enhancer of zeste homolog 2 (EZH2) to the promoter of p21. |
| Pubmed ID | 30215547 |
| Year | 2018 |
| Title | LncRNA DUXAP10 Modulates Cell Proliferation in Esophageal Squamous Cell Carcinoma Through Epigenetically Silencing p21 |
External Links
| Links for DUXAP10 | GenBank HGNC NONCODE |
| Links for esophageal squamous cell carcinoma | OMIM COSMIC |